Trials / Completed
CompletedNCT04507269
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Brii Biosciences Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIR-2218 | VIR-2218 given by subcutaneous injection |
| DRUG | Placebo | Saline given by subcutaneous injection |
Timeline
- Start date
- 2020-08-18
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2020-08-11
- Last updated
- 2024-08-26
- Results posted
- 2024-08-26
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04507269. Inclusion in this directory is not an endorsement.